ProCE Banner Activity

BMT CTN 1507: Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults With Severe Sickle Cell Disease

Conference Coverage

BMT CTN 1507 study showed that reduced intensity haploidentical bone marrow transplant in adults with SCD leads to 2-year event-free survival rates consistent with matched sibling donor myeloablative bone marrow transplant with durable donor engraftment at 2 years and low mortality.

Released: December 14, 2023


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AbbVie Inc., AstraZeneca, Daiichi Sankyo, Inc., Merck Sharp & Dohme LLC, Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals, Inc, and Seagen Inc.

AbbVie Inc.


Daiichi Sankyo, Inc.

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

Regeneron Pharmaceuticals, Inc

Seagen Inc.